Roche applies for approval of its new drug faricimab
By Lee, Tak-Sun | translator Alice Kang
21.12.24 12:06:12
가나다라
0
Improved convenience by 16-weekly dosing, improved convenience… targets the 13 trillion won global market
Will compete with Eylea and Beovu… under review for approval in the US, EU, and Japan
The company had submitted an application for faricimab in the US, Europe, and Japan. If approved, the drug will be competing with Bayer’s ‘Eylea (aflibercept)’ and Novartis’ ‘Beovu (brolucizumab-dbl)’ in the next-generation treatment market for macular degeneration.
According to the industry on the 24th, Roche applied for the marketing authorization of ‘faricimab’ to the Ministry of Food and Drug Safety. Faricimab was registered under the brand name ‘Bavismo inj.’ in Korea.
Faricimab is the first bispecific antibody treatm
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)